Literature DB >> 6819360

Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis.

P N Sambrook, C D Browne, G D Champion, R O Day, J B Vallance, N Warwick.   

Abstract

Treatment terminations with gold sodium thiomalate (GST) in 200 patients with rheumatoid arthritis (RA) were analyzed using the life table method. The termination rate was 27% at 6 months, 48% at 12 months and 84% at 48 months. The major reason for termination was mucocutaneous reaction. Pretreatment clinical and laboratory status of the RA did not influence terminations significantly. Concurrent administration of oral corticosteroids had no significant effect on gold terminations. Complete control of synovitis was achieved in 38% of patients by a median time of 6 months but sustained for greater than 12 months in only 19%.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6819360

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs.

Authors:  M J Wijnands; M A Van 't Hof; M A Van Leeuwen; M H Van Rijswijk; L B Van de Putte; P L Van Riel
Journal:  Pharm World Sci       Date:  1993-10-15

Review 2.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?

Authors:  H A Capell; D R Porter; R Madhok; J A Hunter
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

Review 4.  Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?

Authors:  Alexandros Drosos
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods.

Authors:  R D Situnayake; K A Grindulis; B McConkey
Journal:  Ann Rheum Dis       Date:  1987-03       Impact factor: 19.103

Review 6.  Disease-modifying antirheumatic drugs. Potential effects in older patients.

Authors:  G Gardner; D E Furst
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

7.  Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.

Authors:  J De La Mata; F J Blanco; J J Gómez-Reino
Journal:  Ann Rheum Dis       Date:  1995-11       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.